Overview

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Riociguat